RT Journal Article
SR Electronic
T1 Theranostics in Neurooncology: Heading Toward New Horizons
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 167
OP 173
DO 10.2967/jnumed.123.266205
VO 65
IS 2
A1 Tolboom, Nelleke
A1 Verger, Antoine
A1 Albert, Nathalie L.
A1 Fraioli, Francesco
A1 Guedj, Eric
A1 Traub-Weidinger, Tatjana
A1 Morbelli, Silvia
A1 Herrmann, Ken
A1 Zucchetta, Pietro
A1 Plasschaert, Sabine L.A.
A1 Yakushev, Igor
A1 Weller, Michael
A1 Glas, Martin
A1 Preusser, Matthias
A1 Cecchin, Diego
A1 Barthel, Henryk
A1 Van Weehaeghe, Donatienne
YR 2024
UL http://jnm.snmjournals.org/content/65/2/167.abstract
AB Therapeutic approaches to brain tumors remain a challenge, with considerable limitations regarding delivery of drugs. There has been renewed and increasing interest in translating the popular theranostic approach well known from prostate and neuroendocrine cancer to neurooncology. Although far from perfect, some of these approaches show encouraging preliminary results, such as for meningioma and leptomeningeal spread of certain pediatric brain tumors. In brain metastases and gliomas, clinical results have failed to impress. Perspectives on these theranostic approaches regarding meningiomas, brain metastases, gliomas, and common pediatric brain tumors will be discussed. For each tumor entity, the general context, an overview of the literature, and future perspectives will be provided. Ongoing studies will be discussed in the supplemental materials. As most theranostic agents are unlikely to cross the blood–brain barrier, the delivery of these agents will be dependent on the successful development and clinical implementation of techniques enhancing permeability and retention. Moreover, the international community should strive toward sufficiently large and randomized studies to generate high-level evidence on theranostic approaches with radioligand therapies for central nervous system tumors.